|Phase :||Étude observationnelle|
|Étape du traitement :||Stade métastatique 1er ligne|
|Date d'ouverture :||01/04/2022|
|Date clôture :||31/03/2025|
|Promoteur :||Nantes University Hospital|
|Progression du cancer:||Loco-régional et à distance|
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration.
Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.
The phycocyanin (PC), a biliprotein pigment and an important constituent of the blue-green alga Spirulina platensis, has been reported to possess significant antioxidant and radical-scavenging properties, offering protection against oxidative stress.
Study hypothesis is that phycocyanin may give protection against oxaliplatin-induced neuropathy in the treatment of gastro intestinal cancers including oesogastric, colo-rectal and pancreatic cancers. This trial will be a randomised placebo-controlled study.
- Cancers digestifs
- Tumeur maligne de l'oesophage - Cim10 : C15
- Tumeur maligne de l'estomac - Cim10 : C16
- Tumeur maligne du côlon - Cim10 : C18
- Tumeur maligne du rectum - Cim10 : C20
- Tumeur maligne du pancréas - Cim10 : C25